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ARTICLE  INFO ABSTRACT
Background: Data regarding the prognostic value of androgen receptor (AR) 
expression in locally advanced breast cancer (LABC) is limited. We aimed to 
determine the pathological complete response, defined as ypT0/is and ypN0, in a 
group of patients with AR-positive breast cancer after preoperative treatment. 
Methods: We evaluated immunohistochemical AR expression in 40 patients 
treated in our referral center. Univariate and multivariate models were used to 
assess the association between AR expression and pathological complete response 
(pCR). 
Results: AR expression varied from 75% in estrogen receptor-positive tumors 
to 11.7% in triple-negative tumors (P < 0.001). Three patients with AR-positive 
tumors achieved pCR. In the univariate model, AR expression was significantly 
associated with the absence of pCR (OR = 0.18; 95% CI, 0.04–0.75; P = 0.023). 
After adjusting for intrinsic breast cancer subtypes, AR-positive tumors had less 
probability of achieving a pCR compared with AR-negative ones  (OR = 12.33;
 P = 0.046). 
Conclusions: AR expression was negatively correlated with pCR in our subset 
of patients with LABC who underwent neoadjuvant chemotherapy.  
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and evaluating the possibility of breast- conservation 
surgery. Furthermore, if these patients achieve a 
pathological complete response (pCR) after 
neoadjuvant chemotherapy (defined as ypT0/is 
3
ypN0),  their long-term outcomes can improve. 
Pathological complete response has been associated 
with longer event-free survival and overall survival 
(OS), especially in triple-negative tumors and 
3-5
HER2-positive breast cancers.  
Previous studies have demonstrated the 
prognostic role of androgen receptor (AR) 
expression in breast cancer patients. Overall, AR-
positive tumors are associated with better outcomes 
6, 
and longer OS compared with AR-negative tumors.
7
 However, few studies have evaluated the predictive 
value of AR expression regarding pCR in the 
neoadjuvant setting, and they have yielded 
8, 9
conflicting results.  
In this exploratory study, we aimed to determine 
Introduction
Breast cancer is the leading cause of cancer death 
in women worldwide. In developing countries, high 
breast cancer mortality can be attributable to the 
large proportion of patients with locally advanced 
1
breast cancer (LABC) at diagnosis.  In Costa Rica, a 
middle-income country, LABC comprises around 
2
one-third of newly diagnosed cases.  
For patients with LABC, preoperative chemoth-
erapy provides a reasonable mean for decreasing the 
tumor burden, assessing in vivo chemosensitivity,
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the association between AR expression and pCR in a 
subset of patients treated with preoperative 
chemotherapy for LABC.
Methods
The study protocol was approved by the 
institutional ethics committee and conducted 
according to the Helsinki declaration and its 
modifications.
We prospectively reviewed the clinical records of 
a sample of 40 patients who underwent neoadjuvant 
chemotherapy for LABC and who were treated in our 
referral center (Hospital México, San José, Costa 
Rica). The Breast Tumor Board decided to offer 
preoperative systemic treatment to patients with 
clinical stage IIIA or more (not for stage IV), and to 
patients in whom the relationship between tumor 
size and breast size could imply an up-front 
mastectomy instead of breast-conservation surgery. 
We excluded the patients who did not complete the 
preoperative systemic treatment schedule and those 
who refused surgical treatment. AR expression, as 
well as the presence or absence of estrogen receptors 
(ER), progesterone receptors (PR), or human 
epidermal growth factor receptor 2 (HER2), was 
determined in formalin-fixed, paraffin-embedded 
t i ssues  by  immunohis tochemis t ry  before 
preoperative treatment (DACO diagnostic Glostrup, 
Denmark; clone AR441; clone ERSP1; clone 
PgR636 and polyclonal HER2). Tumors with ≥1% 
nuclear-stained cells were considered positive for 
AR, ER, and PR. Immunohistochemical staining for 
HER2 was scored from 0 to 3+ according to the 
10
guidelines for HercepTest™ (DACO, Denmark).  
HER2 was considered positive when strong (3+) 
membranous staining was observed, whereas cases 
with 0 or 1+ were considered negative. In the case of 
samples scored 2+, a FISH assay was carried out 
using the PathVysion HER2 DNA Probe Kit (Abbott, 
Illinois, USA) according to the manufacturer’s 
protocol. Breast tumor intrinsic subtypes were 
11
defined according to previous recommendations.  
Tumor stage was defined according to the criteria set 
by the Seventh American Joint Committee on 
Cancer. Histologic grading followed the World 
Health Organization classification. The pathologist 
in charge performed the aforementioned histological 
determinations before preoperative treatment and 
after surgery. The same pathologist also determined 
the criteria of pCR in case of absence of invasive 
tumor in the primary site and absence of metastases 
in the harvested lymph nodes (ypT0/is ypN0).  
Preoperative chemotherapeutic scheme for each 
patient included one of the following combinations: 
2 2
5-fluorouracil 500 mg/m , epirubicin 100 mg/m , and 
2
cyclophosphamide 500 mg/m  every 21 days for 4 
2
cycles, followed by weekly paclitaxel 80 mg/m  for 
12 weeks (FE C + T); the same regimen with 
100  w
trastuzumab 6 mg/kg loading dose followed by 4 
mg/kg weekly for one year in the case of HER2-
positive tumors (FE C + T+Tz); epirubicin 100 
100 w
2 2
mg/m  and cyclophosphamide 600 mg/m  every 15 
days for 4 cycles (EC ); or weekly paclitaxel 80 
dd
2
mg/m  for 12 weeks with trastuzumab 6 mg/kg 
loading dose followed by 4 mg/kg per week for one 
year ( T+Tz). The surgery was performed by the 
w
oncologist surgeon in charge 4 or 10 weeks after the 
last dose of chemotherapy.   
Statistical Analysis
Categorical variables are presented as percen-
tages, and the chi-square test or the Fisher exact test 
were applied to compare them. The chi-square test 
for trend was applied to compare AR expression 
among breast cancer subtypes. A logistic regression 
was carried out to assess the relationship between AR 
expression and the probability of achieving a pCR, 
using breast tumor intrinsic subtypes as covariates. A 
P value of less than 0.05 was considered statistically 
significant. Data were analyzed using SPSS for Mac 
20.0 (Chicago, IL).
Results
General characteristics of the studied population 
are presented in Table 1. Overall, 19 patients 
exhibited AR positivity (47.5%). The AR expression 
was associated with HER2, ER, and PR co-
expression. AR expression varied from 75% in ER-
positive tumors to 11.7% in triple-negative tumors 
(Trend test: P < 0.001). Figure 1 shows positive and 
negative samples for AR immunohistochemistry.
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Figure 1. Androgen receptor–positive (A) and receptor–negative (B) breast cancers 
according to immunohistochemical analysis
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Table 1. General characteristics of the studied population 
Age (years, SD)
Stage
Grade 
   
Intrinsic subtype
T
N
T1c
T2
T3
T4a
T4d
N0
N1
N2
N3
1
2
3
Luminal A 
Luminal B 
HER2-enriched
Triple-negative
53.3 ± 10.3
2 (5)
9 (22.5)
24 (60)
3 (7.5)
2 (5)
13 (32.5)
18 (45)
7 (17.5)
2 (5)
2 (5)
19 (47.5)
19 (47.5)
 
3 (7.5)
9 (22.5)
11 (27.5)
17 (42.5)
48.22 ± 8.2
0 
4 (19.1)
13 (61.9)
2 (9.5)
2 (9.5)
4 (19.1)
8 (38.1)
7 (33.3)
2 (9.5)
0
7 (33.3)
14 (66.7)
1 (4.7)
2 (9.5)
3 (14.3)
15 (71.5)
54.6 ± 12.3
2 (10.5)
5 (26.3)
11 (57.9)
1 (5.3)
0
9
10
0
0
2 (10.5)
12 (63.2)
5 (26.3)
2 (10.5)
7 (36.8)
8 (42.2)
2 (10.5)
0.44
0.72
0.66
0.9
<0.001
Variable All patients
(N = 40) 
AR negative 
(N = 21) 
AR positive 
(N = 19) 
P-value
* Statistically significant at P < 0.05
Table 2. Odds of pathological complete response according to the immunohistochemical expression of breast
 cancer receptors 
AR+ (%)
ER+ (%)
HER2+ (%)
ER-/PR-/HER2- (%)
3 (15.8)
2 (13.3)
6 (35.3)
7 (41.2)
0.18 (0.04-0.75)
0.25 (0.05-1.35)
1.17 (0.31-4.44)
1.87 (0.50-7.19)
0.023
0.09
0.82
0.28
0.08 (0.01-0.97)
0.41 (0.17-1.44)
1.33 (0.63-3.77)
1.83 (0.41-6.72)
0.046
0.44
0.12
0.32
Receptor  pCR  Univariate 
odds ratio (95% CI) 
 Adjusted 
odds ratio** (95% CI) 
P-value
AR: androgen receptor; ER: estrogen receptor; HER2: human epidermal growth factor type 2; pCR: pathological complete response;
 PR: progesterone receptor. * Statistically significant at P < 0.05 ** Adjusted for breast cancer intrinsic subtype
After preoperative chemotherapy, a breast-
conservation surgery was possible in 22 patients 
(55%), and the rest of them underwent for 
mastectomy. Pathological complete response 
(ypT0/is ypN0) was achieved in 13 patients (33%). 
Only 3 patients (15.8%) with AR-positive tumors 
achieved a pCR. The rate of pCR according to the 
expression or absence of AR, ER, PR, and HER2 are 
demonstrated in Table 2. AR-positive tumors had 
82% less chance of achieving a pCR compared with 
patients with AR-negative tumors (OR = 0.18; 95% 
After adjusting for each intrinsic breast cancer 
subtype (Table 2), the absence of AR was 
independently associated with the probability of 
achieving a pCR (OR = 0.08; P = 0.046), meaning 
that the chance of achieving pCR was 92% higher in 
AR-negative tumors than in AR-positive breast 
cancer. The Cox-Snell R2 for this model was 0.21, 
meaning that only 21% of the pCR rate could be 
explained by this regression model.  Figure 2 shows 
one tumor with pCR and another sample with 
residual disease.        
P-value
Figure 2. Complete pathological response (A) and residual disease (B) in two breast
 cancer samples after neoadjuvant chemotherapy
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Discussion
Pathological complete response after preope-
rative chemotherapy is a valuable clinical endpoint 
because it has been associated with favorable long-
3
term outcomes in patients with LABC,  especially 
for those with HER2 tumors and TNBC. Although 
some predictive markers have been developed to 
assess the probability of achieving this endpoint, 
there is still limited data on the relationship between 
AR expression and pCR. This possible relationship 
can be beneficial for improving the understanding 
and treatment of this particular subset of breast 
cancer patients. 
In this short report, AR expression was positive in 
47.5% of the patients, while previous studies have 
demonstrated a higher AR expression (70–80%). 
One reason for this inconsistency could be the cancer 
type, which in our study included mainly HER2-
positive and triple-negative tumors. It has been well 
established that AR expression varies according to 
12-14
the breast cancer intrinsic subtype.  For example, 
Collins and colleagues reported the positivity of AR 
expression in 88% of ER-positive tumors, while only 
14
32% of TNBC were AR-positive.  Although the 
representativeness of ER-positive tumors was low, 
our data was in accordance with such distribution 
because the majority of ER-positive tumors also 
exhibited AR expression.
Our findings demonstrated an inverse association 
between AR expression and the probability of 
achieving a pCR. Similar results have been reported 
by Loibl and colleagues, who showed that AR 
negativity predicts the odds of achieving pCR. 
Specifically, these authors reported a pCR rate of 
12.8% in AR-positive tumors, while patients with 
AR-negative breast cancer had a pCR rate of 25.4% 
9
(P < 0.0001).  On the contrary, Masuda and 
colleagues did not find any significant association 
between AR expression (determined by immuno-
histochemistry) and pCR in a cohort of 33 patients 
with triple-negative breast cancer (TNBC) who 
15
underwent preoperative chemotherapy.  These 
divergent results can be attributable to a lower 
statistical power due to small sample size, as well as 
the spectrum of patients as Masuda et al., only 
15
included TNBC patients in their study.  It has been 
demonstrated that patients with triple-negative 
breast cancer and AR expression have a very low 
16
pCR rate in comparison with other TNBC subtypes.  
Our results are in accordance with this finding as the 
majority of patients with TNBC who achieved a pCR 
did not express AR on immunohistochemical 
analyses. 
Having a small sample size and a unicenter design 
limit generalizability of our findings. Furthermore, 
information bias might have occurred if patients 
were misclassified by immunohistochemistry, 
although we tried to eliminate this bias by choosing 
only one experienced pathologist to report all  
samples. 
In summary, our findings showed the predictive 
value of AR expression in patients with LABC 
undergoing neoadjuvant chemotherapy. However, 
we must notice that pCR rate can vary according to 
the presence of some other clinical variables, such as 
ER and HER2 expression. Further research is 
warranted to establish the role of androgens in breast 
cancer patients.
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